NeuBase Therapeutics (NBSE), a key player in the Biotechnology sector, has been experiencing a challenging period with a net income loss of $33.8 million. The company's shares are currently trading well below their 52-week high of $5.4, hinting at potential undervaluation. The Wall Street target price stands at $140, suggesting a substantial upside. However, it's worth noting the high level of short interest in the stock, with 199.8K shares short as of last month. As we move into April, the question is whether NeuBase is poised for a rebound. Its Beta of 1.013 suggests it generally moves in line with the broader market, and the accumulation distribution indicator of 0.0485 might signal that the stock is being accumulated. The company's valuation real value is reported at $35.71, which significantly exceeds its current market value of $1.03, potentially indicating an undervalued situation. Many millennials are steering clear of the biotech sector, but it's worth taking a closer look at NeuBase Therapeutics to understand its current market trends. Previously, we suggested that NeuBase Therapeutics was entering a dip as shareholders became more bearish due to heightened sector volatility. NeuBase Therapeutics' performance barely mirrors the market, and its returns over the past few months seem uncorrelated with overall market returns. However, the company's solid basic indicators may suggest a short-term price drift for shareholders. NeuBase Therapeutics is set to announce its earnings tomorrow.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of NeuBase Therapeutics. In general, sophisticated investors focus on analyzing NeuBase Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build NeuBase Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of NeuBase Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for NeuBase Therapeutics, many experienced traders also check how macroeconomic factors affect NeuBase Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of NeuBase Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How does NeuBase Stands against Peers?
Analyzing NeuBase Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to NeuBase Therapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
NeuBase Therapeutics Competition DetailsCloser look at NeuBase Therapeutics Semi Variance
NeuBase Therapeutics has current Semi Variance of 9.32. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.
Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.
Semi Variance | = | SUM(RET DEV)2N(ZERO) |
| = | 9.32 |
| SUM | = | Summation notation |
| RET DEV | = | Actual return deviation over selected period |
| N(ZERO) | = | Number of points with returns less than zero |
Let's now compare NeuBase Therapeutics Semi Variance to its closest peers:
| NBSE | 9.321193473707817 |
| KO | 0.4 |
| CMG | 0.12 |
| KRUS | 5.35 |
| YUM | 0.52 |
Every cloud has a silver lining, and for NeuBase Therapeutics (NBSE), April could be the month where the sun starts to shine.
Despite a high probability of bankruptcy at 95.99%, the company's strong current ratio of 7.53X and substantial working capital of $20.48M suggest it has the liquidity to weather the storm. The stock's 52-week high of $5.4 also indicates potential for a significant rebound from its current typical price of $1.01. However, investors should be cautious as the company's net income shows a loss of $33.8M from continuing operations. With a Wall Street target price of $140, the potential upside is significant, but the risk is equally high. .
Will NeuBase Therapeutics latest dip continue?
NeuBase Therapeutics' Total Risk Alpha has risen to -0.02, indicating a potential risk increase. This suggests the stock price may dip soon. Investors should monitor the stock closely due to its current risk profile and the possibility of a continued downward trend. NeuBase Therapeutics exhibits above-average downside volatility. Investors are advised to further inspect NeuBase Therapeutics and ensure their
market timing and asset allocation strategies align with the company's future alpha estimation. As a potential penny stock, NeuBase Therapeutics may offer investment opportunities, but it's crucial to understand the inherent risks. Penny stocks are often speculative and subject to artificial price hype. Investors should be wary of email spams, unreported promotions, sudden news releases, and other hype signals. It's also advisable to check the biographies and work history of company officers before investing. While it's possible to profit from NeuBase Therapeutics with perfect timing, remember that artificially hyped penny stocks often fail to maintain their increased share price. Long-term shareholder value can only be increased through solid performance backed by strong fundamentals.
Our Final Take On NeuBase Therapeutics
Although few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, NeuBase Therapeutics may offer a potential longer-term growth to shareholders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither purchase nor exit any shares of NeuBase Therapeutics at this time. The NeuBase Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NeuBase Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Nico Santiago is a PR Contributor to Macroaxis Editorial Board. Nico is a relatively new author here at Macroaxis and he likes to work on advertising and sponsored content and marketing for the company. Nico spends most of his time surfing when the weather is nice and he spends the rest of the year writing for various blogs and companies, as he works on his upcoming books, The Rise of the Financial Machines and Time Series Modelling with AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nico Santiago do not own shares of NeuBase Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com